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Objective: To evaluate the clinicopathologic characteristics and prognostic factors of ovarian granulosa cell tumors.
Methods: Medical records of 113 patients presenting between January 1995 and December 2007 were retrospectively reviewed. 
Results: One-hundred two patients had adult type disease, with a mean age of 46.2 years (range, 18 to 83 years) and a mean 
follow-up period of 54.7 months (range, 1 to 155 months). The distribution of FIGO stages was 86 patients at stage I, 11 at stage 
II, and 5 at stage III. During follow-up, ten patients recurred at a mean time of 48 months (range, 4 to 109 months). Among them, 
three patients died after a mean of 57 months (range, 25 to 103 months). In recurrence analysis, advanced stage (p=0.032) and 
presence of residual disease (p=0.012) were statistically significant, and age<40 years, premenopause and positive washing 
cytology were marginally significant (p<0.1). In multivariate analysis, stage was the only factor associated with recurrence; 
adjuvant chemotherapy and fertility-sparing surgery were not statistically significant. Among 36 patients with fertility-sparing 
operations, eight patients had nine pregnancies and delivered seven babies. Eleven patients had juvenile type tumors; the 
mean age was 20.0 years (range, 8 to 45 years) and the mean follow-up period was 69.8 months (range, 20 to 156 months). The 
distribution of FIGO stage was nine patients at stage I and two at stage III. There were no recurrences or deaths reported. Four 
patients had seven pregnancies and delivered six babies.
Conclusion: Stage is the only factor associated with disease-free survival, and fertility-sparing surgery may be a treatment option 
for women with early-stage disease who want to retain fertility.
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INTRODUCTION
Granulosa cell tumors of the ovary (GCTs), first described by 
Rokitansky [1], are rare malignancies that account for approxi-
mately 3-5% of ovarian tumors [2,3]. There are two distinct 
histological types - adult GCT (AGCT) and juvenile GCT (JGCT). 
AGCTs are more common and are usually seen in perimeno-
pausal and postmenopausal women, with a peak incidence 
at 50-55 years. JGCTs are rare tumors, representing 5% of all 
GCTs and occurring in premenarchal girls and young women 
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[4]. 
Because these tumors are rare and recur 5 to 30 years after 
initial diagnosis [5], there are few studies on the prognostic 
factors for AGCT and JGCT with an adequate number of pa-
tients and a sufficiently long follow-up period. The aims of 
this study are to evaluate the clinicopathologic characteristics 
of GCT and to determine the prognostic factors affecting the 
disease-free interval. 
MATERIALS AND METHODS
Between 1995 and 2007, 113 new diagnoses of GCT were 
made across five hospitals; 102 patients were diagnosed with 
AGCT and 11 patients were diagnosed with JGCT. Data was 
retrospectively collected from medical records, including pa-
tient characteristics, clinical presentation, pathologic reports, 
extent of surgery, postoperative adjuvant therapy, recurrence, 
and follow-up status. The disease-free interval was defined as 
the time from the date of initial operation to the date of recur-
rence or the date of the final follow-up. 
Statistical analysis was performed using SPSS ver. 12.0 (SPSS 
Inc., Chicago, IL, USA). The Kaplan-Meier method was used to 
assess the disease-free interval, and multivariate analyses were 
performed using the Cox regression model. A p-value of <0.05 
was considered to be statistically significant.
RESULTS
1. Adult granulosa cell tumor
One-hundred two patients (90.3%) were diagnosed with 
AGCTs; clinicopathologic characteristics and treatment me-
tho  ds are summarized in Tables 1 and 2. Age at diagnosis ran-
ged from 24 to 83 years, with a mean age of 47.1 years. The 
peak incidence was in the fifth decade, and 60 patients (58.8%) 
were postmenopausal. The mean gravity and parity were 3.5 
and 2.3, respectively. Vaginal bleeding (28.4%) and palpable 
abdominal mass (28.4%) were the most common presenting 
symptoms, followed by abdominal pain (17.6%), amenorrhea 
(3.9%), and other symptoms (2.9%). Only 23 patients (22.5%) 
were asymptomatic. The mean tumor diameter was 9.7 cm 
(range, 3 to 24 cm). The tumors were right-sided in 52 pa  tients 
(55.9%), left-sided in 48 patients (47.1%), and bilateral in two 
patients (2.0%). Preoperative CA-125 was checked in 76 pa-
tients, with only ten patients (9.8%) having an elevated level 
(>35 IU/mL). Endometrial evaluation was available in 68 pa-
tients (66.7%); results included ten (9.8%) cases of simple hy-
perplasia without atypia, one (1.1%) case of sim  ple hyperplasia 
with atypia, two (2.0%) cases of complex hyperplasia without 
aty  pia, three (2.9%) cases of complex hyperplasia with atypia, 
and two (2.0%) cases of endometrial cancer. Eighteen patients 
(17.6%) had endometrial abnormalities, and one patient with 
endometrial cancer died due to recurrence.
Table 1. Clinical characteristics of adult granulosa cell tumors
Characteristic No. (%)
Age
  <30 8 (7.4)
  30-39 26 (25.5)
  40-49 31 (30.4)
  50-59 19 (18.6)
  ≥60 18 (17.6)
Menopause
  No 60 (58.8)
  Yes 42 (41.2)
Parity
  0 19 (18.6)
  1 11 (10.8)
  2 33 (32.4)
  >3 39 (38.2)
CA-125
  Normal 66 (64.7)
  Elevated 10 (9.8)
  Not measured 26 (25.5)
Ascites
  No 83 (81.4)
  Yes 19 (18.6)
Stage
  I 86 (84.3)
  II 11 (10.8)
  III 5 (4.9)
Operation method
  Fertility sparing surgery
    USO 27 (26.5)
    USO+staging operation 6 (5.9)
    Cystectomy 3 (2.9)
  Non-fertility sparing surgery
    H and BSO 29 (28.4)
    Staging operation 37 (36.3)
Treatment modality
  Surgery only 70 (68.6)
  Surgery+chemotherapy 32 (31.4)
USO, unilateral salpingo-oophorectomy; H and BSO, hysterectomy 
and bilateral salpingo-oophorectomy.In Ho Lee, et al.
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All patients underwent surgical procedures. Ascites was pres-
ent in 19 patients (18.6%), and six patients (5.9%) were cancer 
cell-positive. Peritoneal cytologies including ascites or wash-
ings were available in 57 patients (55.9%), and 12 patients 
(11.8%) showed positive for cancer cells. Preoperative rupture 
was seen in 18 patients (17.6%), with 16 cases (15.7%) of rup-
ture occurring during surgery. Capsule invasion was seen in 
ten patients (9.8%). For the treatment of the primary tumor, 
37 patients (36.3%) underwent a staging operation, 29 (28.4%) 
underwent hysterectomy and bilateral salpingo-oophorecto-
my, 27 (26.5%) underwent unilateral salpingo-oophorectomy, 
six (5.9%) underwent unilateral salpingo-oophorectomy in-
cluding a staging operation, and three (2.9%) underwent cys-
tectomy. The distribution of staging was 86 (843.3%) at stage I, 
11 (10.8%) at stage II, five (4.9%) at stage III, and none at stage 
IV. Complete resection was performed in 100 patients (98.0%), 
whereas two patients (2.0%) underwent incomplete resection 
(with about 95% percent of the tumor removed).
Postoperative chemotherapy was administered in 31 pa-
tients (30.4%). The regimens included bleomycin, etoposide, 
and cisplatin (BEP) in 24 patients; cyclophosphamide, adria-
mycin, and cisplatin (CAP) in five patients; vincristine, bleomy-
cin, and cisplatin (VBP) in one patient; and cyclophosphamide, 
pirarubicin, and cisplatin in one patient.
The mean follow-up period was 54.7 months (range, 1 to 155 
months). Recurrence was observed in ten patients (9.8%), 
and the mean time from initial surgery to recurrence was 
48 months (range, 4 to 92 months). In recurrence analysis, 
advanced stage (p=0.032) and presence of residual disease 
(p=0.012) were statistically significant, while age<40 years, 
premenopause, and positive washing cytology were margin-
ally significant (p<0.1). Tumor size, bilateral tumors, capsule 
invasion, ascites, tumor rupture, operation type, postoperative 
chemotherapy, and elevated CA-125 were not associated with 
Table 2. Pathologic characteristics of adult granulosa cell tumors
Characteristic No. (%)
Size 　
  <10 57 (55.9)
  10-19 40 (39.2)
  ≥20 5 (4.9)
Site 　
  Right 52 (51.0)
  Left 48 (47.1)
  Bilateral 2 (2.0)
Capsule invasion 　
  No 92 (90.2)
  Yes 10 (9.8)
Peritoneal cytology 　
  Negative 46 (45.1)
  Positive 12 (11.8)
  Not measured 44 (43.1)
Rupture 　
  No 68 (66.7)
  During operation 16 (15.7)
  Ruptured state 18 (17.6)
Endometrial status 　
  Normal 50 (49.0)
  Simple hyperplasia without atypia  10 (9.8)
  Simple hyperplasia with atypia 1 (1.1)
  Complex hyperplasia without atypia 2 (2.0)
  Complex hyperplasia with atypia 3 (2.9)
  Endometrial cancer 2 (2.0)
  Not measured 34 (33.3)
Residual lesion 　
  No 100 (98.0)
  Yes 2 (2.0)
Table 3. Disease-free interval based on clinical characteristics
Variable Mean±SE 
(95% CI) (mo) p-value
Age 0.068
  <40 114±14 (87-141)
  ≥40 123±5 (113-134)
Menopause 0.051
  No 119±11 (98-140)
  Yes 127±3 (120-133)
Treatment modality 0.407
  Surgery only 130±10 (110-151)
  Surgery+chemotherapy 115±8 (100-130)
Ascites 0.676
  No 129±9 (112-147)
  Yes 114±10 (94-134)
Stage 0.032
  I 131±9 (113-148)
  II 122±11 (100-144)
  III 68±19 (31-106)
Operation type 0.956
  Fertility sparing operation 141±8 (126-156)
  Non-fertility sparing operation 114±7 (101-127)
CA-125 0.570
  Normal 140±9 (123-157)
  Elevated 117±12 (93-141)
SE, standard error; CI, confidence interval.Multicenter study of ovarian granulosa cell tumors
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recurrence (Tables 3 and 4). In multivariate analysis, stage was 
the only factor associated with recurrence (Table 5). Recur-
rence rates associated with stage were 8.1% (7/86) in stage I, 
9.1% (1/11) in stage II, and 40.0% (2/5) in stage III. During the 
follow-up period, three patients died of disease at a mean 
time of 69 months (range, 42 to 103 months), two patients 
had stage III disease and one patient had stage II disease.
Of the 36 patients (35.3%) receiving a fertility-sparing op-
eration, eight patients had a total of nine pregnancies. All 
patients had stage I disease, with the exception of one patient 
with stage II disease. Six patients delivered seven healthy ba-
bies at term; one patient was lost to follow-up at 10+4 weeks. 
The last patient delivered one healthy baby and recurred at 
the second pregnancy, so she underwent hysterectomy with 
a staging operation.
Table 4. Disease-free interval according to pathologic characteristics
Variable Mean±SE (95% CI) (mo) p-value
Rupture 0.653
  No 128±10 (108-148)
  Yes 117±8 (101-132)
Washing cytology 0.099
  Negative 119±6 (108-131)
  Positive 103±15 (73-132)
Capsule invasion 0.321
  No 131±8 (115-147)
  Yes 88±11 (66-110)
Site 0.158
  Unilateral 131±8 (115-147)
  Bilateral 73±24 (25-120)
Size 0.778
  <10 117±7 (104-131)
  ≥10 129±11 (107-150)
Residual lesion 0.012
  No 131±8 (116-147)
  Yes 42±2 (37-46)
SE, standard error; CI, confidence interval.
Table 5. Multivariate analysis
Variable
Hazard 
ratio
95.0% confidence 
interval
p-value
Age ≥40 yr 0.54 0.12-2.50 0.433
Postmenopause 0.19 0.02-1.83 0.149
Residual lesion 1.08 0.06-20.02 0.960
Stage III 9.88 1.13-86.34 0.038
Table 6. Clinicopathologic characteristics of juvenile granulosa cell 
tumors
Characteristic No. (%)
Age 　
  <10 1 (9.1)
  10-19 6 (54.5)
  20-29 2 (18.2)
   ≥30 2 (18.2)
Size 　
  <10 3 (27.3)
  10-19 7 (63.6)
  ≥20 1 (9.1)
Symptoms 　
  Abdominal mass 5 (45.5)
  Vaginal bleeding 3 (27.3)
  Abdominal pain 2 (18.2)
  Asymptomatic 1 (9.1)
Stage 　
  I 9 (81.8)
  III 2 (18.2)
CA-125 　
  Normal   5 (45.5)
  Elevated 5 (45.5)
  Not measured 1 (9.1)
Ascites 　
  No 8 (72.7)
  Yes 3 (27.3)
Peritoneal cytology 　
  Negative 9 (81.8)
  Positive 0 (0.0)
  Not measured 2 (18.2)
Rupture 　
  No 8 (72.7)
  During surgery 3 (27.3)
Operation methods 　
  Cystectomy 1 (9.1)
  USO 3 (27.3)
  USO+staging operation 6 (54.5)
  H and BSO 1 (9.1)
Treatment modalities 　
  Surgery only 8 (72.7)
  Surgery+chemotherapy 3 (27.3)
Residual lesion 　
  No 11 (100.0)
  Yes 0 (0.0)
USO, unilateral salpingo-oophorectomy; H and BSO, hysterectomy 
and bilateral salpingo-oophorectomy.In Ho Lee, et al.
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2. Juvenile granulosa cell tumors
JGCT was diagnosed in 11 patients (9.7% of GCTs). Clini  co-
pa  tho  logic characteristics and treatment methods are sum-
marized in Table 6. The mean age was 20.0 years (range, 8 
to 45 years), although more than half of the patients were 
diag  nosed prior to the age of 20, and five patients (45.5%) 
were premenarchal. With the exception of one, all patients 
had symptoms. The most common symptom was abdominal 
mass (45.5%), while three patients presented with vaginal 
bleeding (27.3%) and two patients presented with abdominal 
pain (28.3%). The mean tumor diameter was 12.4 cm (range, 5 
to 26 cm), and all tumors were unilateral (right-sided in seven 
patients [63.6%] and left-sided in four [50.0%]). Preoperative 
CA-125 was measured in ten patients, with only five patients 
(45.5%) having elevated levels (>35 IU/mL).
All patients initially underwent surgical treatment. Surgery 
included unilateral salpingo-oophorectomy with a staging 
operation in six patients (54.5%), unilateral salpingo-oopho-
rectomy in three patients (27.3%), hysterectomy and bilateral 
salpingo-oophorectomy in one patient (9.1%), and cystec-
tomy in one patient (9.1%). Ascites were present in three 
patients (27.3%); no ascites or cytology washes were cancer-
cell positive. Tumor rupture occurred during surgery in three 
patients (27.3%), although capsule invasion was not seen in 
any of the patients. No patients had residual lesions. Nine 
patients (81.8%) had stage I disease, and two patients (18.2%) 
had stage III disease. Three patients (32.3%) received adjuvant 
chemotherapy with BEP.
The mean follow-up period was 69.8 months (range, 20 to 
156 months), and there were no recurrences or deaths. Dur-
ing the follow-up period, four patients had a total of seven 
pregnancies, including six normal deliveries at term and one 
cornual pregnancy.
DISCUSSION
Compared to epithelial ovarian cancers, GCTs have different 
biology and clinical presentation due to their retained ability 
to produce estrogen [6]. Estrogen production results in men-
struation problems and leads to early presentation; as such, 
these tumors are detected 80-90% of the time in stage I [3,7]. 
In our study, 36 patients (31.9%) presented with menstrual 
symptoms such as vaginal bleeding or amenorrhea, and only 
24 patients (21.2%) were symptom-free. Ninety-five patients 
(84.1%) had stage I disease, and only seven patients (6.2%) 
had stage III disease. Also, estrogen production may result in 
endometrial abnormalities; according to the literature, the 
incidence of endometrial carcinoma ranges from 3-22%, and 
that of endometrial hyperplasia ranges from 32-85% [8]. In our 
study of AGCTs, 16 patients had endometrial hyperplasia and 
two had endometrial carcinoma. Therefore, efforts to identify 
associated endometrial abnormalities are required.
There has been some controversy in the detection of prog-
no  stic factors; however, stage is accepted as the most im-
portant prognostic factor in most studies. Published ten-year 
survival rates are 84-95% in stage I, 50-65% in stage II, and 
17-33% in stages III-IV in studies with long follow-up periods 
[9,10]. Similarly, we found that stage was the only factor af-
fecting recurrence in univariate and multivariate analyses. The 
five-year disease-free survival rates were 92% for stage I, 89% 
for stage II, and 50% for stage III.
The effect of age on prognosis has been controversial. Chan 
et al. [11] found that age less than 50 years was an indepen-
dent prognostic factor for improved survival (hazard ratio 
[HR], 0.217; 95% confidence interval [CI], 0.067 to 0.706), and 
Zhang et al. [12] also demonstrated that women under the 
age of 50 years had a 10% survival advantage in a series of 
376 women. However, Ayhan et al. [13] reported that patients 
aged 60 years and younger had longer survival times (154.5 
vs. 89.2 months, p=0.015) and experienced less mortality (4.9% 
vs. 21.1%, p=0.05), but age was not found to be a significant 
prognostic factor in multivariate analysis. In contrast to pre-
vious studies, age less than 40 years was associated with a 
high recurrence rate in our study. The five-year and ten-year 
disease-free survival rates were 82% and 48% for patients ages 
40 years and under, and were 93% and 84% for patients older 
than 40 years, although the difference between the groups 
was only marginally significant (p=0.068). Postmenopausal 
women also had significantly lower recurrence rates than pre-
menopausal women (p=0.051).
Tumor size is another factor that has been controversial, with 
some studies having reported that tumor size is an important 
prognostic factor [7,11]. Miller et al. [14] found that 33% of pa-
tients with recurrence and 13% of patients without recurrence 
had tumors larger than 15 cm, and recurrent patients had 
significantly larger tumors (13.5 cm vs. 10 cm; p=0.029). Other 
studies were unable to validate the prognostic significance of 
tumor size [5,12,15]. There were no differences in recurrence 
and survival based on tumor size (with a cutoff of 10 cm) in 
our study.
As is the case in epithelial ovarian carcinoma, postoperative 
residual lesions have been suggested as an important factor in 
AGCTs. Al-Badawi et al. [16] reported on 55 patients with GCT 
of stage IC or greater. All patients with gross residual disease 
(>2 cm) were dead within four years, and the only statistically 
significant factor affecting survival was the presence of mac-
roscopic residual disease (82% vs. 22%). A recent study also Multicenter study of ovarian granulosa cell tumors
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found that absence of residual disease was an independent 
predictor for improved survival (HR, 0.162; 95% CI, 0.043 to 
0.610) [11]. In our study, patients with residual lesions had a 
lower recurrence rate than that of patients without (50.0% vs. 
9%, p=0.012), but this difference was not significant in multi-
variate analysis.
In our study, we evaluated prognostic factors that had not 
been reported in previous studies. Positive cytology (p=0.099) 
was marginally significant, but bilateral disease, ascites, tumor 
rupture, and capsule invasion were not associated with differ-
ences in recurrence rates. However, there have been few stud-
ies focusing on these factors. In one study, 25-year survival 
rates were 86% in intact stage I patients and 60% in patients 
with ruptured tumors [15]. Further studies with more patients 
are required to demonstrate these results.
Although many chemotherapy regimens have been used 
in ovarian carcinoma, the relatively low incidence and late 
recurrence of GCT leads to difficulty in forming a consensus. 
In addition, there is no evidence that postoperative adjuvant 
chemotherapy prevents recurrence [16-18]. Our study also 
showed that patients who received postoperative chemother-
apy had a high recurrence rate and a low survival rate. This 
result may be due to the high incidence of adjuvant chemo-
therapy in patients with advanced stages. However, Homesley 
et al. [19] have reported the efficacy of BEP in incompletely re-
sected stages II-IV or recurrent disease in a GOG study. Thirty-
seven percent (14/38) of these patients had negative findings 
on second-look laparotomy, and six complete responders 
had a long median duration (24.4 months). Further, Schumer 
and Cannistra [20] reported that the clinical significance of 
postoperative adjuvant chemotherapy for high-risk patients 
has not been demonstrated through prospective randomized 
trials, but that the use of adjuvant chemotherapy and radia-
tion therapy have sometimes been associated with prolonged 
disease-free survival in high-risk patients.
Surgery is the initial treatment for ovarian carcinoma. How-
ever, the extent of the surgical procedure is controversial, 
particularly in JGCT, which presents at a younger age and 
therefore makes fertility-sparing surgery an important is-
sue. Pautier et al. [8] reported that nine patients with stage 
IA tumors and who had undergone radical surgery had no 
relapses, but relapse was observed in three of the six patients 
with stage IA tumors who were treated with conservative 
surgery. Busby and Anderson [21] and Evans et al. [22] also 
found a high relapse rate and a low survival rate associated 
with conservative surgery. However, Norris and Taylor [23] and 
Novak et al. [24] reported no differences in relapse rates be-
tween conservative and radical surgeries for stage IA patients. 
In a recent study, Zhang et al. [12] reported on 132 patients 50 
years of age or younger and who had stage I disease, of which 
61 (46%) underwent standard surgical treatment (including 
hysterectomy) and 71 (54%) had a uterine-sparing procedure. 
The five-year survival rates of these respective women were 
97% and 98%. In our study, 36 patients (35.3%) underwent 
fertility-sparing surgery, and they exhibited no statistically 
significant difference in recurrence or survival compared with 
those having undergone non-fertility-sparing surgery. In this 
study, eight patients experienced a total of nine pregnancies, 
and one patient had stage II disease. Considering the fact that 
AGCT has a good survival rate and a late recurrence pattern, 
fertility-sparing surgery is an option for women with stage I or 
II ovarian carcinoma who wish to retain fertility. Colombo et 
al. [25] concluded that fertility-sparing surgery is a reasonable 
approach if the disease is limited to one ovary. 
JGCTs are also rare, constituting less than 5% of ovarian tu-
mors in children and adolescents. About 90% of patients are 
diagnosed at stage I and have a good prognosis [26]. There 
are reports of advanced-stage tumors successfully treated 
with platinum-based chemotherapy [19,20]. Schneider et al. 
[27] published a prospective study of 54 ovarian sex cord-stro-
mal tumors in children and adolescents, including 45 JGCTs. 
They determined that chemotherapy should be used in stage 
IC tumors with preoperative rupture or malignant ascites, 
especially those tumors with high mitotic activity. Cisplatin-
based chemotherapy seems to be effective for the treatment 
of advanced-stage tumors. In our study, we used adjuvant 
chemotherapy in two patients with stage III disease, and no 
recurrence was detected. Of the two patients with stage IC 
disease, one received adjuvant chemotherapy and one did 
not; neither experienced recurrence.
This study has some weaknesses. First, it is a retrospective 
study. However, due to the rarity and characteristics of these 
tumors, it would be not be possible to execute a prospec-
tive study. We were able to determine the prognostic factors 
affecting disease-free survival after reviewing the medical 
records from five hospitals. Second, several hospitals were 
involved, and each institution had some degree of difference 
in patient management. Currently, there is no consensus on 
the management of these tumors, and the data from this and 
other studies can be used to develop consensus guidelines.
This study also has several strengths. First, it is the first mul-
ticenter study of GCTs in Korea. It is difficult to detect the sta-
tistical significance of these tumors based only on the small 
number of cases from a single institution. Second, some stud-
ies on GCTs have been performed; however, there are only a 
few studies regarding pathologic and operative findings, such 
as ascites, cytology, tumor rupture, capsule invasion, and bilat-
erality. Third, we reported not only on AGCTs but also on the In Ho Lee, et al.
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less-common JGCTs and their pregnancy results.
In conclusion, our results show that most AGCTs are detect-
ed in the early stages and have excellent survival outcomes. 
Stage is the only prognostic factor predicting recurrence; ad-
ditional studies about age, menopause, postoperative residual 
lesions, and positive washing cytology are required. The recur-
rence rate observed was not high, but the interval from initial 
surgery to recurrence was relatively long, thus requiring long-
term follow-up. Furthermore, for women with early-stage 
AGCT who want to retain fertility, fertility-sparing surgery with 
or without chemotherapy is a reasonable treatment option 
that does not compromise survival. Our studies of JGCTs dem-
onstrate that prognosis is good, and the same management 
methods can be addressed, although small in numbers. In the 
future, a prospective multicenter study with uniform proto-
cols may be necessary to confirm these results and to study 
additional factors.
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